Literature DB >> 18603409

TRAF6 is a critical signal transducer in IL-33 signaling pathway.

Megumi Funakoshi-Tago1, Kenji Tago, Morisada Hayakawa, Shin-Ichi Tominaga, Tomoyuki Ohshio, Yoshiko Sonoda, Tadashi Kasahara.   

Abstract

IL-33 has been shown to induce Th2 responses by signaling through the IL-1 receptor-related protein, ST2L. However, the signal transduction pathways activated by the ST2L have not been characterized. Here, we found that IL-33-induced monocyte chemoattractant protein (MCP)-1, MCP-3 and IL-6 expression was significantly inhibited in TNF receptor-associated Factor 6 (TRAF6)-deficient MEFs. IL-33 rapidly induced the formation of ST2L complex containing IL-1 receptor-associated kinase (IRAK), however, lack of TRAF6 abolished the recruitment of IRAK to ST2L. Consequently, p38, JNK and Nuclear factor-kappaB (NF-kappaB) activation induced by IL-33 was completely inhibited in TRAF6-deficient MEFs. On the other hand, IL-33-induced ERK activation was observed regardless of the presence of TRAF6. The introduction of TRAF6 restored the efficient activation of p38, JNK and NF-kappaB in TRAF6 deficient MEFs, resulting in the induction of MCP-1, MCP-3 and IL-6 expression. Moreover, IL-33 augmented autoubiquitination of TRAF6 and the reconstitution of TRAF6 mutant (C70A) that is defective in its ubiquitin ligase activity failed to restore IL-33-induced p38, JNK and NF-kappaB activation. Thus, these data demonstrate that TRAF6 plays a pivotal role in IL-33 signaling pathway through its ubiquitin ligase activity.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18603409     DOI: 10.1016/j.cellsig.2008.05.013

Source DB:  PubMed          Journal:  Cell Signal        ISSN: 0898-6568            Impact factor:   4.315


  55 in total

1.  Quantitative phosphoproteomic analysis of IL-33-mediated signaling.

Authors:  Sneha M Pinto; Raja Sekhar Nirujogi; Pamela Leal Rojas; Arun H Patil; Srikanth S Manda; Yashwanth Subbannayya; Juan Carlos Roa; Aditi Chatterjee; T S Keshava Prasad; Akhilesh Pandey
Journal:  Proteomics       Date:  2015-01       Impact factor: 3.984

Review 2.  Interleukin-33 biology with potential insights into human diseases.

Authors:  Gaby Palmer; Cem Gabay
Journal:  Nat Rev Rheumatol       Date:  2011-04-26       Impact factor: 20.543

3.  Interleukin-33 induces growth-regulated oncogene-α expression and secretion in human umbilical vein endothelial cells.

Authors:  Masayoshi Yamamoto; Katsuyuki Umebashi; Akinori Tokito; Junichi Imamura; Michihisa Jougasaki
Journal:  Am J Physiol Regul Integr Comp Physiol       Date:  2017-06-21       Impact factor: 3.619

4.  A network map of IL-33 signaling pathway.

Authors:  Sneha M Pinto; Yashwanth Subbannayya; D A B Rex; Rajesh Raju; Oishi Chatterjee; Jayshree Advani; Aneesha Radhakrishnan; T S Keshava Prasad; Mohan R Wani; Akhilesh Pandey
Journal:  J Cell Commun Signal       Date:  2018-04-28       Impact factor: 5.782

5.  IL-33 synergizes with IgE-dependent and IgE-independent agents to promote mast cell and basophil activation.

Authors:  Matthew R Silver; Alexander Margulis; Nancy Wood; Samuel J Goldman; Marion Kasaian; Divya Chaudhary
Journal:  Inflamm Res       Date:  2009-09-18       Impact factor: 4.575

Review 6.  Novel Biomarkers in Heart Failure Beyond Natriuretic Peptides - The Case for Soluble ST2.

Authors:  Antonio J Vallejo-Vaz
Journal:  Eur Cardiol       Date:  2015-07

7.  IL-33 markedly activates murine eosinophils by an NF-κB-dependent mechanism differentially dependent upon an IL-4-driven autoinflammatory loop.

Authors:  Carine Bouffi; Mark Rochman; Christopher B Zust; Emily M Stucke; Andrey Kartashov; Patricia C Fulkerson; Artem Barski; Marc E Rothenberg
Journal:  J Immunol       Date:  2013-09-16       Impact factor: 5.422

Review 8.  Disease-associated functions of IL-33: the new kid in the IL-1 family.

Authors:  Foo Y Liew; Nick I Pitman; Iain B McInnes
Journal:  Nat Rev Immunol       Date:  2010-01-18       Impact factor: 53.106

Review 9.  The IL-33/ST2 pathway: therapeutic target and novel biomarker.

Authors:  Rahul Kakkar; Richard T Lee
Journal:  Nat Rev Drug Discov       Date:  2008-10       Impact factor: 84.694

Review 10.  Type I IL-1 receptor (IL-1RI) as potential new therapeutic target for bronchial asthma.

Authors:  Jyh-Hong Lee; Li-Chieh Wang; Hsin-Hui Yu; Yu-Tsan Lin; Yao-Hsu Yang; Bor-Luen Chiang
Journal:  Mediators Inflamm       Date:  2010-07-05       Impact factor: 4.711

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.